A carregar...
Update on the use of rituximab for intractable rheumatoid arthritis
It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an inadequate response to anti-TNF therapies. Since approval rituximab has bec...
Na minha lista:
| Publicado no: | Open Access Rheumatol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5074725/ https://ncbi.nlm.nih.gov/pubmed/27789983 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|